Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN, IINNW))), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology ("HYLA") into an immediate personalized Blood Lab Test, aimed at performing real-time patient blood work for the rapid detection in minutes of the potential development of an underlying life-threatening medical condition.
The HYLA business model is designed to replace the need for nurses to take intermittent physical blood samples from patients undergoing extracorporeal procedures by providing patient blood work with pre-determined setup options, or alternatively, supporting physical immediate intermittent blood work testing and analysis. The HYLA is expected to be used near a patient's bed in ER's, ICU's, Medical Units and in operating rooms, with the potential to replace expensive equipment, eliminate the need for blood cartridges and dependency on central labs and reduce the burden on hospital staff. The HYLA technology could also potentially reduce countless tests performed each year where valuable time is often lost between the time of ordering a blood test and when test results are received, which can impact patient treatment and outcomes.
The HYLA is undergoing clinical evaluations in Sheba Hospital (Ranked 9th in the world by Newsweek magazine) in patients undergoing open-heart procedures, in preparation of the Company's planned U.S. Food and Drug Administration ("FDA") submission of the first configuration of the HYLA in 2025.
